WO2002015876A3 - Amorphous carrier materials for drug delivery - Google Patents

Amorphous carrier materials for drug delivery Download PDF

Info

Publication number
WO2002015876A3
WO2002015876A3 PCT/GB2001/003676 GB0103676W WO0215876A3 WO 2002015876 A3 WO2002015876 A3 WO 2002015876A3 GB 0103676 W GB0103676 W GB 0103676W WO 0215876 A3 WO0215876 A3 WO 0215876A3
Authority
WO
WIPO (PCT)
Prior art keywords
carrier materials
drug delivery
amorphous carrier
amorphous
hdc
Prior art date
Application number
PCT/GB2001/003676
Other languages
French (fr)
Other versions
WO2002015876A2 (en
Inventor
Julian Blair
Jaap Kampinga
Original Assignee
Quadrant Healthcare Uk Ltd
Julian Blair
Jaap Kampinga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Healthcare Uk Ltd, Julian Blair, Jaap Kampinga filed Critical Quadrant Healthcare Uk Ltd
Priority to AU2001278622A priority Critical patent/AU2001278622A1/en
Publication of WO2002015876A2 publication Critical patent/WO2002015876A2/en
Publication of WO2002015876A3 publication Critical patent/WO2002015876A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Abstract

Amorphous hydrophobically-derivatised carbohydrates (HDC) are used as effective carrier materials to deliver microparticles of a therapeutic agent to the lung.
PCT/GB2001/003676 2000-08-21 2001-08-16 Amorphous carrier materials for drug delivery WO2002015876A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001278622A AU2001278622A1 (en) 2000-08-21 2001-08-16 Amorphous carrier materials for drug delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0020616.9 2000-08-21
GB0020616A GB0020616D0 (en) 2000-08-21 2000-08-21 Particulates

Publications (2)

Publication Number Publication Date
WO2002015876A2 WO2002015876A2 (en) 2002-02-28
WO2002015876A3 true WO2002015876A3 (en) 2002-08-01

Family

ID=9898041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/003676 WO2002015876A2 (en) 2000-08-21 2001-08-16 Amorphous carrier materials for drug delivery

Country Status (3)

Country Link
AU (1) AU2001278622A1 (en)
GB (1) GB0020616D0 (en)
WO (1) WO2002015876A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846894B2 (en) 2002-02-20 2014-09-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
GB0124710D0 (en) * 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
GB0208608D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB0210771D0 (en) * 2002-05-10 2002-06-19 Univ London Pharmacy Derivatised particulate inhalation carriers
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2006066907A1 (en) * 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
JOP20120023B1 (en) 2011-02-04 2022-03-14 Novartis Ag Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
DK3212212T3 (en) 2014-10-31 2020-12-21 Univ Monash POWDER FORMULATION

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003978A1 (en) * 1994-08-04 1996-02-15 Quadrant Holdings Cambridge Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
WO1998029097A1 (en) * 1996-12-31 1998-07-09 Quadrant Holdings Cambridge Limited Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
WO1999033853A2 (en) * 1997-12-23 1999-07-08 Quadrant Holdings Cambridge Limited Carbohydrates, useful in solid delivery systems
WO2001003673A1 (en) * 1999-07-12 2001-01-18 Quadrant Healthcare (Uk) Limited Dry powder compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003978A1 (en) * 1994-08-04 1996-02-15 Quadrant Holdings Cambridge Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
WO1998029097A1 (en) * 1996-12-31 1998-07-09 Quadrant Holdings Cambridge Limited Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
WO1999033853A2 (en) * 1997-12-23 1999-07-08 Quadrant Holdings Cambridge Limited Carbohydrates, useful in solid delivery systems
WO2001003673A1 (en) * 1999-07-12 2001-01-18 Quadrant Healthcare (Uk) Limited Dry powder compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846894B2 (en) 2002-02-20 2014-09-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

Also Published As

Publication number Publication date
AU2001278622A1 (en) 2002-03-04
GB0020616D0 (en) 2000-10-11
WO2002015876A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
WO2002015876A3 (en) Amorphous carrier materials for drug delivery
AU2001238386A1 (en) Medication delivery devices
IL157771A0 (en) Intravaginal drug delivery devices for the administration of an antimicrobial agent
AU2003297621A1 (en) Medical devices for delivery of therapeutic agents
AU2002318759A1 (en) Remedies for diseases with bone mass loss having EP4 agonists as the active ingredient
AU2997500A (en) Single dose delivery device
AU2003210001A1 (en) Medicament delivery device
AU4460900A (en) Carrier patch for the delivery of agents to the skin
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
AU2001261425A1 (en) Cases for medication delivery devices
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
AU2003221770A1 (en) Controlled release transdermal drug delivery
AU2003223005A1 (en) Application device for topical administration of pharmaceutical agents
AUPR553701A0 (en) A device for the delivery of a drug to a fractured bone
AU2002353444A1 (en) Integrated transdermal drug delivery system
AU2001277171A1 (en) Catheter for target specific drug delivery
AU2003301405A1 (en) Prepolymeric materials for site specific delivery to the body
AU2002308289A1 (en) Highly flexible transdermal therapeutic system having nicotine as active substance
MXPA03007903A (en) Highly flexible transdermal therapeutic system having nicotine as active substance.
AU2003243439A1 (en) Medical device for intra-lumenal delivery of pharmaceutical agents
AU2003301444A1 (en) System for delivery of active substances
AU2003231260A1 (en) Catechin multimers as therapeutic drug delivery agents
IL151922A0 (en) Transdermal therapeutic system for the delivery of lerisetron
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
AU2003226770A1 (en) Intravaginal reservoir drug delivery devices

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP